Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of ABT-089 in Alzheimer's Disease
NCT00069849Phase 2Terminated
- Sponsor
- Abbott Laboratories
- Start
- Jul 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pozanicline in Alzheimer's disease (AD) (4 arms), sponsored by Abbott Laboratories. Primary endpoint: Mini-Mental State Examination. Started Jul 2003; status: terminated.
02
Drugs
pozanicline
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00069849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00069849.